Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CBER’s Goodman Eyes Tissue, Blood Test Innovation Through Post-9/11 Lens

This article was originally published in The Gray Sheet

Executive Summary

Development of tests to screen blood and tissues for multiple pathogens would help safeguard public health and national security, Center for Biologics Evaluation & Research Director Jesse Goodman, MD/MPH, stresses in an Aug. 19 New England Journal of Medicine editorial

You may also be interested in...

Tissue Donor Eligibility Rule Issued; FDA Good Tissue Practices Rule Awaited

FDA's tissue donor eligibility final rule will go into effect May 25, 2005, one year after its publication in the Federal Register

McClellan’s FDA Legacy? Decisive Role In Product Development Priorities

FDA's "critical path" initiative to help streamline R&D costs and product development schedules is positioning the agency to eventually seek grant-making authority from Congress

Colorectal, Bladder Cancer Therapies Are Top Prospects For April US FDA Approvals

Sanofi’s next-generation meningococcal vaccine, broader use of Bristol-Myers Squibb’s Reblozyl move toward approval; United Therapeutics foreshadows Trevyent regulatory difficulties.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts